[{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s First Semaglutide Obesity Trial Hits The Mark","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Reports Weight Loss of 14.9% (16.9% if taken as intended) in STEP 1 trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for US FDA Regulatory Approval of Once-Weekly Semaglutide 2.4 mg For Weight Management","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Semaglutide Injection Effective in Weight Loss Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk to Initiate Phase 3a Development in Obesity With Oral Semaglutide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults with Obesity or Overweight in SURMOUNT-1","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's SURMOUNT-1 Results Published in the New England Journal of Medicine Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss in Adults With Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Innovent Biologics"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Closes Financing Agreement with Oberland Capital","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Innovent Biologics"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Semaglutide 50 mg Achieved 15.1% Weight Loss (17.4% if all People Adhered to Treatment) in Adults with Obesity or Overweight in the OASIS 1 Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tirzepatide Demonstrated Significant and Superior Weight Loss Compared to Placebo in two Pivotal Studies","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Eli Lilly"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Semaglutide 2.4 mg Reduces the Risk of Major Adverse Cardiovascular Events by 20% in Adults with Overweight or Obesity in the SELECT Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Novo Nordisk"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and Without Diabetes, Cardiovascular Disease and Chronic Kidney Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Boehringer Ingelheim GmbH"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
BI 456906 (survodutide) is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist, which is investigated for the treatment of treatment for acquired hypothalamic obesity.
Wegovy (once-weekly subcutaneous semaglutide 2.4 mg) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.
Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner. it is being investigated for weight loss in adults with obesity and type 2 diabetes.
Wegovy® (semaglutide) is targeting GLP-1 receptor prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.
IBI362 (mazdutide) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.
Adlumiz (anamorelin) is a selective, novel, orally active ghrelin receptor agonist. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism.
IBI362 (also known as mazdutide), a GLP-1R and GCGR dual agonist, is a long-acting synthetic peptide related to mammalian oxyntomodulin (OXM) with a fatty acid side chain attached thereto.
Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones.
Mounjaro (tirzepatide) met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimands.